AnGes To Withdraw, Refile HGF Gene Therapy In Japan

If finally fully approved in its first indication, the HGF gene therapy could become a first-in-class therapy for PAD - but only after years of challenges in clinical trials.

AnGes will once pull out Collategen from the Japanese market, and then refile for approval.
AnGes will pull Collategene from Japanese market then refile for approval • Source: Shutterstock

Japanese gene therapy venture AnGes, Inc. has decided to withdraw an application for the full approval in Japan of its hepatocyte growth factor (HGF) gene therapy Collategene (beperminogene perplasmid), for severe peripheral vascular disease (PVD).

The product obtained Japanese conditional approval in 2019 and had been filed for full approval in 2023. But a post-marketing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Japan

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By 

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting reimbursement prices. How has the sector panned out over the last decade?

Japan Recommends Donanemab, Sets Raft Of New And Reduced Prices

 
• By 

A Japanese approval for Lilly's Alzheimer's drug donanemab is expected soon following a positive recommendation from the MHLW. The ministry has also announced reimbursement prices for 12 new products including Fabhalta, along with price cuts for Tezspire, Dupixent and competitors following a review.

More from Asia

Easing Market Entry: Japan’s PMDA Allows Approval Filings In English

 
• By 

Non-Japanese firms without offices in the country may submit documents for approval filings in English, subject to certain conditions.

Akebia’s Vafseo: Japanese Postmarketing Data, Narrowed Indication Eased Liver Toxicity Worries

 
• By 

The Pink Sheet Drug Review Profile explores the US FDA’s approval of vadadustat to treat anemia in chronic kidney disease patients on dialysis. A complete response letter cited the risk of drug-induced liver injury, but postmarketing data from Japan reassured reviewers.

India And Pakistan Boost Transparency In Industry-Doctor Interactions

 
• By 

Developments in India and Pakistan are designed to standardize how drug companies disclose their expenses associated with health care professionals.